Aktuellt
SENASTE
At SEB's Nordic Seminar, OssDsign's CEO Morten Henneveld talked about the study results released yesterday that confirmed the pre-clinical data. The TOP FUSION study is a first-in-patient study and the results showed a 93% fusion rate after 12 months. It is a small study, but together with the safety report and 2,000 patients treated, it gives an indication that the product is working as intended.
LÄS MER
